During the quarter, India sales were up 11% to Rs 177 crore in Q4 March 2020 as compared to Rs 159 crore in Q4 March 2019. As per IQVIA MAT March 2020, the company posted a healthy growth of 11% in Cardiology (segment growth of 11%), 17% in Ophthalmology (segment growth of 11%), 6% in Dermatology (segment growth of 9%) and 16% in Pain Management (segment growth of 12%).
Total exports soared 43% to Rs 490 crore in Q4 March 2020 from Rs 343 crore in Q4 March 2019. The pharma companys emerging market branded generic sale surged 38% year-on-year basis to Rs 304 crore in Q4 March 2020. US generic sale stood at 143 crore, recording a sensational growth of 88% on year on year basis in Q4 March 2020.
The company said R&D expenses were at Rs 50 crore in Q4 March 2020, (Q4 FY 2019 Rs 40 crore) which is 7% of operating revenue.
Ajanta Pharmas consolidated net profit surged 21% to Rs 467.70 crore on 25.9% rise in net sales to Rs 2587.87 crore in the year ended March 2020 (FY20) over the year ended March 2019 (FY19). PBT rose 29.11% to 663.97 crore in FY20 over FY19.
Ajanta Pharma is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
Powered by Capital Market - Live News